<DOC>
	<DOC>NCT02974829</DOC>
	<brief_summary>The purpose of this study is to conduct an investigator initiated observational study to continue to follow up the China subset of study participants for another 5 years after they complete participation in the REALM Study</brief_summary>
	<brief_title>REALM China Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>1. Patients completed REALM Study in China 2. Patients willing to sign the consent to continue antiviral treatment or posttreatment follow up, and agree his/her legacy data and blood/liver histology samples collected in REALM Study may be used for the analyses planned for this new study. 1. Patients who do not provide consent to participate in this study; 2. Patients are formally enrolled into any investigational drug clinical trial after the REALM study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>